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Brief Communication
Detection of Minimal Residual Disease in B Cell Acute
Lymphoblastic Leukemia Using an Eight-Color Tube
with Dried Antibody Reagents
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1Assistance Publique Hôpitaux de Marseille, Laboratoire d’Hématologie, Hôpital de la Timone, Marseille, France
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Background: Flow cytometry is a powerful tool for the detection of minimal residual disease (MRD) of B cell
precursor acute lymphoblastic leukemia (BCP-ALL) patients. However, the staining process and the choice of
antibodies rely on laboratory expertise and may be source of variability or technical errors. Recently, Beckman
Coulter commercialized a ready to use tube with dried format reagents for BCP-ALL MRD detection. The aim of
this study is to evaluate the applicability of this tube and to compare it to a conventional (liquid format
reagents) method.
Methods: Thirty-one samples from B ALL patients were analyzed: 19 bone marrow (BM) aspirations,
10 peripheral blood (PB) samples and 2 cerebrospinal ﬂuids at different stages of the follow-up. In addition,
we tested 5 bone marrow samples mixed into non-pathological (control) bone marrow. The dried format tube
included seven antibodies: CD45Kro, CD58FITC, CD34ECD, CD10PC5.5, CD19PC7, CD38AA700, CD20AA750,
with possibility of additional antibodies for blast markers identiﬁed at diagnosis. For comparison, a liquid for-
mat tube was prepared, and considered as the reference.
Results: This tube was validated for daily routine laboratory, with satisfying qualitative (MRD + or MRD−)
and quantitative (MRD percentages) correlation with the reference tube.
Conclusion: With this single dried format tube, we showed interesting results for BCP-ALL MRD detection in
the aim of standardization and reliable interlaboratory results. It allows accurate MRD detection including low
levels (10–4), and offers possibility to increase performance (supplementary antibody) within a preestablished
effective antibody panel for BCP-ALL MRD. © 2019 International Clinical Cytometry Society
Key terms: ﬂow cytometry; B cell acute lymphoblastic leukemia; minimal residual disease detection; Dura-
clone; dried reagents.
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Minimal residual disease (MRD) assessment repre-
sents a predictive and independent risk factor and a
useful tool in the clinical management of B-cell precur-
sor (BCP) acute lymphoblastic leukemia (ALL) (1,2).
Two methods coexist for studying MRD: Multipara-
metric Flow Cytometric (MFC) analysis of leukemia-
associated immunophenotypes (LAIP) and polymerase
chain reaction (PCR) ampliﬁcation of antigen receptor
rearrangements (3). Garand et al. have demonstrated in
a multicenter study that PCR and MFC are highly com-
plementary strategies for MRD detection in ALL (4) and
several studies have shown that the use of multicolor
(>6 markers) immunostainings combined with the
introduction of speciﬁc newly described markers signif-
icantly improved FCM-MRD analysis in BCP-ALL (5–8).
Among the advantages of the FCM, the possibility to
have results just a few hours after sample collection is
highly appreciated by clinicians, especially for patients
who need a speciﬁc care.
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Nevertheless, the workﬂow in clinical ﬂow cytometry
laboratories must constantly be reviewed to develop
technical procedures that improve quality and produc-
tivity, and reduce costs. Indeed, clinical ﬂow cytometry
laboratories face discrepancies due to pipetting errors,
short shelf life of products, planiﬁcation of cocktail
reagents, lot to lot potential variation, and some lack of
standardization.
Classically (and it is the case for our laboratory), a
combination of 8 to 10-color tubes is used to analyze
MRD at different time points (peripheral blood or bone
marrow MRD analysis). In this context, Beckman
Coulter® recently introduced a range of dried reagents
with a speciﬁc tube for the detection of B Acute Lym-
phoblastic Leukemia MRD called “Duraclone® Rare
Events ALB” (RE-ALB).
The aim of this study is to evaluate the applicability
of the RE-ALB tube in routine laboratory and test per-
formances of this dried format reagent when compared
to the currently used liquid format reagent cocktail
(control tube).
MATERIALS AND METHODS
Patients and Samples
Twenty-two children (15 girls and 6 boys) with a de
novo diagnosis of B-lineage ALL were considered for
enrollment. Informed consent was obtained from par-
ents/guardians and study protocols were approved by
the ethics committee of Marseille University Hospital.
Samples from these patients were analyzed by morpho-
logical examination and ﬂow cytometry in our
laboratory.
Overall, 31 samples from B ALL patients were ana-
lyzed: 19 bone marrow (BM) aspirations, 10 peripheral
blood (PB) samples and 2 cerebrospinal ﬂuids (CSF) at
different stages of the follow-up: during the corticother-
apy (n = 11), at the end of induction (MRD1; n = 8), at
the end of consolidation (MRD2; n = 6), at relapse
(n = 3), and at other time points (OTP; n = 3). In addi-
tion, ﬁve bone marrow samples were diluted into a
non-pathological bone marrow. Finally, samples from
patients with cytopenia but without any malignant cells
were used as control samples. These control subjects
matched on age with pediatric patients.
Patients and samples characteristics are summarized
in Table 1.
Sample Preparation
PB and BM samples were processed for ﬂow cytome-
try analysis within 24 h after collection. In order to
identify MRD at low level (10−3 or 10−4), we must
enrich the sample by performing erythrocyte prelysis
on a maximal number of cells before staining. Red
blood cells were ﬁrst lysed using NH4Cl solution and
the remaining cells were sequentially centrifuged
(600 G) for 10 min, washed twice in phosphate buff-
ered saline (PBS: pH 7.2) and resuspended in PBS. PB
and BM samples were diluted in order to obtain 106
cells in 100 μl. Secondly, cells were incubated in the
dark at room temperature for 15 min with the antibody
cocktail. On the other hand, CSF samples were directly
incubated with the cocktail without lysing and washing
steps.
The liquid reagent tube was tested in parallel and
considered as the reference. This tube included seven
ﬂuorochrome-conjugated liquid antibodies with
CD45Krome Orange (J.33), CD10FITC (ALB1), CD34
ECD (581), CD58PC5 (AICD58), CD19PC7 (J3-119),
CD38APC (HB-7), CD20 AA750 (B9.E9 [HRC20]).
The Duraclone® tube included seven Beckman Coulter
ﬂuorochrome-conjugated dried antibodies: CD45Krome
Orange (J.33), CD58FITC (AICD58), CD34ECD (581),
CD10PC5.5 (ALB1), CD19PC7 (J3-119), CD38 AA700
(LS198-4-3), CD20 AA750 (B9.E9 [HRC20]).
FL2 channel was used to add a blast-speciﬁc marker
(LAIP) antibody conjugated with PE, which was the
same for liquid or dried reagent experiments. As a
result, each tube contained eight antibodies. Data were
immediately acquired.
Flow Cytometer and Quality Control
The instrument used was a Navios (Beckman Coulter®,
Miami, FL). Daily controls were run, including Flow
Check and Flow Set Pro Fluorospheres™ (Beckman
Coulter) to monitor the instrument performance and
Immuno-Trol™ Cells as part of the electronic Interna-
tional Quality Assurance Program (www.beckmancoulter.
com). As the ﬂuorochromes differed between the two test
tubes, different settings and a different compensation
matrix were used for the Duraclone® tube.
Compensations were made using dried-antibody
coated single color tubes of the Compensation Kit pro-
vided for Duraclone tests, according to manufacturer’s
instructions.
Analysis Data
Analysis of ﬂow cytometry results was made using
Kaluza software (Beckman Coulter). As usually in FCM-
MRD analysis, we did not analyze MFIs of each isolated
marker but studied correlation between the two stain-
ing methods on the obtained MRD quantitation’s. Three
observers analyzed each MRD positive and negative
case. Results were conﬁrmed by double blinded
analyses.
Of note, because several tandem dye are used in the
two format (dry and liquid tubes), the stability of these
tandem dye (PC5, AA700…) are periodically controlled
by searching a positive interference-signal in the poten-
tially affected channel (PE or APC channel) depending
on the considered tandem.
Statistical Evaluation
Results have been evaluated both qualitatively and
quantitatively.
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In the quantitative comparison, the two methods
of FCM data were evaluated using nonparametric
Spearman correlation statistics. All calculations were
performed with Prism GraphPad Software®.
RESULTS
Applicability of the RE-ALB tube
Several control bone marrow samples were ﬁrst run
with the Duraclone tube for “backbone marker” dried
antibody validation and to test the reliability of this
method for B lymphoid cells analysis (example: Fig. 1A).
When compared to counterpart liquid tube, the different
cellular populations were positioned as expected, nota-
bly on the SS versus CD45 cytogram. The same number
of cells was analyzed, (approximatively 1 million) and
the same percentage of B lymphocytes was observed for
both approaches (12%). Moreover, no cluster or signiﬁ-
cant number of cells could be observed in the “blast”
corresponding Boolean gate (last SS/CD45 plot, “blasts”
circle zone, left or right Fig. 1A), conﬁrming there was
no pathological cell in the sample.
In order to further evaluate the technical perfor-
mances of the dry format tube, we mixed ﬁve patholog-
ical bone marrow samples at diagnosis into non-
pathological bone marrow containing immature B cells
(hematogones) for detection quantitation of blast cells
mixed with physiological B cell precursors (CD10
+/CD19+ characterized cells). We tested each diluted
sample (1/10 and 1/100 dilution) with both standard
and Duraclone approaches and conﬁrmed that there is
an excellent agreement between the two methods for
blast detection (e.g., 1/10 diluted blast cells = 4.1%
FIG. 1. (A) Control bone marrow sample stained with liquid format reagents (left) and dried format reagents (right): granulocytes in red, monocytes in
green, mature T lymphocytes in blue, mature B lymphocytes in purple and physiological B cell precursors (hematogones) in turquoise blue. The “Cell”
gate allows the exclusion of nonviable cells, fragment cells, and residual red blood cells. Events within the “Cell” gate are then analyzed according to
the expression of CD19 in order to isolate B lymphoid cells. CD19 positive cells are studied through biparametric cytograms showing CD10 expression
for immature B cells. The last cytogram (SS/CD45) shows events resulting from a Boolean gate, which includes regions as expected for typical blast
cells in B-ALL based on diagnosis characterization (on CD10/CD38 and CD10/CD58 cytograms for example), and excludes mature B lymphocytes
(on CD10/CD20 cytogram). (B) Quantitative correlation of the CD19+/CD45+ ratio; dried reagent tube on the X axis and liquid tube on the Y axis. Red
dots represent PB and blue dots represent BM samples. (C) Bone Marrow MRD positive sample: stained with liquid format reagents (left) and dried
format reagents (right). Blasts are represented in black, B mature lymphocytes in purple and hematogones in turquoise blue. MRD percentage was
evaluated at 0.03% by the two approaches. (D) MRD quantitative concordance between the two approaches (dried or liquid). Red dots represent PB and
blue dots represent BM samples.
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[dried tube] vs 4.2% [liquid tube]; 1/100 diluted blast
cells = 0.3% [dried tube] vs 0.3% [liquid tube]) (Data not
shown).
Comparison and validation of the RE-ALB tube
performances
Twenty-nine cellular suspensions from B ALL
patients were next analyzed: 10 derived from PB and
19 from BM aspirates. For these samples, we analyzed
the number of CD45+ and CD19+ events, calculated a
CD19+/CD45+ ratio, and compared this ratio between
the two methods, using nonparametric Spearman corre-
lation statistics. As expected, we found a strong correla-
tion between liquid and dry reagents (r = 0,9747;
p < 0.0001) (Fig. 1B).
Then, we tracked potential blast cells in all samples
tested in duplicate and concluded whether MRD was
detected or not. The minimal amount of detectable
blasts required to consider MRD as positive was a clus-
ter of 10 to 20 events and the MRD result was given as
the percentage of blasts present within total nucleated
cells expressing CD45. If the MRD is undetectable, the
detection threshold depends on the total number of
analyzed cells. PB MRD assessment was performed at
early time points of treatment (during or just after the
prephase of corticotherapy) explaining the lower num-
ber of cells analyzed in PB samples. We were able to
analyze at least 20,000 cells in the PB and at least
200,000 cells for the BM samples (in order to reach usu-
ally expected thresholds of 10−3 to 10−4, respectively).
To reach the highest possible detection performance,
as well as endorse the use of additional liquid markers
in dried tube, MRD detection for both methods was
always made with the use of an additional patient-
speciﬁc LAIP marker (identiﬁed at diagnosis), allowed
by the use of an additional PE-coupled antibody for
each tube. Comparison of the two formats demon-
strated excellent agreement. Indeed, 23 samples were
found positive by both methods. An example of BM
positive samples for both liquid and dried format
reagents is represented in Figure 1C (left: liquid, right:
dried). MRD detection by both approaches was 0.03%.
For the 23 positive samples, MRD percentages were
highly concordant between the two methods with
r = 0.9913 and a P value <0.0001 (Fig. 1D).
We also tested two CSF in the context of extramedul-
lary relapse suspicion of B-ALL, but only with the Dura-
clone tube as we did not have enough sample volume
to test it in duplicate. Despite a low cell count (between
10,000 and 20,000 in the tested samples), this approach
allowed accurate detection and quantitation of patho-
logical cells in CSF (Data not Shown).
In addition, six samples were negative by both
methods with a comparable detection threshold in all
cases (four samples with a 10−4 sensitivity threshold
and two with a 10−3 sensitivity threshold).
DISCUSSION
Studies of MRD are becoming central to the clinical
management of patients with acute leukemia. Flow
cytometry provides fast and reliable results, but dis-
crepancies may appear due to antibody cocktails vari-
ability and technical errors. We have evaluated here
results obtained with a single tube containing dried
antibody cocktail for B ALL MRD detection and
quantitation.
The basic approach of ﬂow cytometry-based MRD
analysis is to differentiate the residual leukemic blasts
from normal B cell precursors (BCP) also known as
hematogones, and other B lymphoid cells, based on the
aberrant expression or deviation from the normal pat-
tern of expression of a variety of antigens (9,10). The
Duraclone dried tube contains seven different anti-
bodies including the CD45/CD19/CD10 triad used for
almost every B ALL MRD detection; they are considered
as “backbone” markers. Other markers such as CD20,
CD34, CD58, and CD38, are useful markers allowing
lymphocytes, lymphoblastic and hematogones cells dis-
crimination. Additional markers can be used for up to
10 color upgraded tube, allowing additional leukemia
associated immunophenotype (LAIP) detection (CD73,
CD86…) (7,11,12).
According to the manufacturer, 106 cells should be
suspended in 100 μl for each test. This is in line with
recommendations for MRD analysis (13) and what is
applied in our laboratory. However, high level of cellu-
larity could not be reached in every case, especially for
PB MRD detection during or after corticotherapy.
Despite these various cellularity conditions, correlations
between the two methods showed highly comparable
results.
To our knowledge, few studies have been published
using the dried tube technology to screen hematologi-
cal malignancies. In 2015, a Canadian study showed
qualitative and quantitative equivalency between dried
and liquid reagents for screening lymphoproliferative
syndromes (14). In 2017, these results have been
conﬁrmed by other authors who used a 10 color tube
containing 15 dried antibodies for screening lympho-
proliferative malignancies (15). Finally, some authors
tested the Duraclone technology for screening lympho-
proliferative and myelodysplasic syndromes with a
10-color 14-antibody tube, proving this tube was
useful in 60% of cases with signiﬁcant time and cost
savings (16). Another study aimed to compare dried
tube immunophenotyping with liquid reagent method,
assaying mean ﬂuorescence intensities (MFI) for both
methods (17) in the context of lymphocytosis or
immune deﬁciency. This study revealed comparable
results for MFI obtained with dried and liquid tubes.
Here, on a clinical approach, we further investigated
if the endpoint results could be correlated as well, in
the context of BCP-ALL MRD detection. Consistently,
MRD detection obtained with the Duraclone technology
was highly comparable with the liquid-antibody tube
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method. One interesting point is our demonstration
that using additional LAIP markers to upgrade to an
eight-color tube led to detection of low MRD level, with
strong correlation when compared to liquid format
tube. We tested several potential blast markers, such as
lineage aberrant markers (CD33 or CD13), or some
more recently described aberrant markers for BCP-ALL
such as CD49f, CD66c, or CD123 ((11); (12)). These
additional markers allowed quite low detection thresh-
old, with comparable detection performance for dried
versus liquid tube.
To conclude, we report here the ﬁrst work aiming to
study B ALL MRD detection by ﬂow cytometry using a
multicolor dried antibody single tube. We demonstrate
the applicability of the Duraclone RE ALB tube in daily
routine as we have shown a qualitative and quantitative
correlation with the conventional approach (liquid
reagent). This technology offers time saving
(no cocktail preparation needed), elimination of pipet-
ting errors, reduces potential waste of antibodies and
promotes interlaboratory standardization. Performances
may even be increased using 9 or 10 color tube when
combining with other LAIPs when possible. This dried
tube could be particularly appropriate for early MRD
evaluation or in case of relapse suspicion (blood or
CSF), and complies for standardization effort and work-
ﬂow optimization.
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